Kallikrein 9 antibody (C-Term)

Catalog No. ABIN3031531

Product Details anti-Kallikrein 9 Antibody

Target: Kallikrein 9 (KLK9)

Binding Specificity: C-Term

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Kallikrein 9 antibody is un-conjugated

Application: Western Blotting (WB)

Purification: Antigen affinity

Immunogen: An amino acid sequence from the C-terminus of human Kallikrein 9 (SVCHYLDWIQEIMEN) was used as the immunogen for this Kallikrein 9 antibody.

Isotype: IgG

Application Details

Application Notes: The stated application concentrations are suggested starting amounts. Titration of the Kallikrein 9 antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL

Restrictions: For Research Use only

Handling

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Storage: -20 °C

Storage Comment: After reconstitution, the Kallikrein 9 antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Target Details for Kallikrein 9

Target: Kallikrein 9 (KLK9)

Alternative Name: Kallikrein 9 (KLK9 Products)

Synonyms: KLK-L3 antibody, KLKL3 antibody, 1200016C12Rik antibody, AI324041 antibody, Klk9 antibody, Klks3 antibody, rGK-9 antibody, rK9 antibody, kallikrein related peptidase 9 antibody, kallikrein related-peptidase 9 antibody, kallikrein 1-related peptidase C9 antibody, KLK9 antibody, Klk9 antibody, Klk1c9 antibody

Background: Kallikrein-related peptidase 9, also known as KLK9 or KLK-L3, belongs to the kallikrein subgroup of serine proteases, which have diverse physiologic functions in many tissues. The KLK9 gene contains 5 coding exons and is mapped to 19q13.41. The gene is regulated by steroid hormones in a human breast cancer cell line. Yousef et al.(2001) performed a quantitative analysis of KLK9 expression in ovarian cancer. The results indicated that KLK9 is under steroid hormone regulation in ovarian and breast cancer cell lines. KLK9 is a potential independent favorable prognostic marker for early-stage, low-grade, optimally debulked ovarian cancer patients.

UniProt: Q9UKQ9

Pathways: Complement System